Skip to main
Reviews PT-141

A skeptical reading of the PT-141 (bremelanotide) evidence — what the trials measured, what they did not.

About this project

About Reviews PT-141

A garnet-ruled appraisal of the PT-141 (bremelanotide) research record — each finding beside its caveat.

What this site is

Reviews PT-141 is an appraisal bench for the peer-reviewed research on PT-141 (bremelanotide) — a desk where each study is summarized and then weighed for how well it was actually done. Nothing is treated, diagnosed, or prescribed at this bench, and no medical advice leaves it; there is no clinic behind it and no clinician on staff. It makes nothing, stocks nothing, and sells nothing — it reads the published record and appraises it, full stop.

What "reviews" means here

The word "reviews" in our name is editorial, not commercial. We do not host customer reviews, product ratings, or vendor listings, and we do not facilitate access to any compound. "Reviews" describes the work: reading the published studies on bremelanotide and appraising how well they were done — effect sizes weighed against placebo, blinded trials separated from open-label data, approved indications kept distinct from off-label and research-chemical claims. The modifier marks a vantage over the literature, not a service on offer.

How we appraise

Every quantitative claim on the bench is fastened to a numbered source on the references page — PubMed-indexed journals, ClinicalTrials.gov-registered trials, and the FDA prescribing information. We lead with the finding and attach its caveat in the same breath — the effect size next to its statistical significance, the open-label limitation next to the durability claim, the disputed study flagged as disputed. We name the boundary between the FDA-approved bremelanotide pharmaceutical and the unregulated research-chemical form on every relevant page. We recommend no dose for any person.

What we are careful never to do

No authors, studies, or affiliations are invented here. There is no physical clinic, no phone line, no clinical staff to claim, and no consultation, prescription, or treatment on offer. We do not name competitor drug brands in our own prose. And we do not blur the line between an anecdote and a trial result — informal reports are labeled as such and kept separate from cited findings. The aim is a sober, accurate digest a curious reader can trust to weigh the evidence fairly.